Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38372597.
- Also identified by DOI 10.1158/1078-0432.CCR-23-3736 and PMC identifier 11062819.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Combination immune-checkpoint inhibition with chemotherapy is a clinical standard, yet concurrent administration may limit the full benefit of immunotherapy by blunting the proliferation and differentiation of CD8 T cells. Identifying patients in whom sequential chemo-immunotherapy or immunotherapy alone is feasible should be a priority to optimize long-term outcomes. See related article by Mariniello et al., p. 1833.
Medical subject headings
- Immunotherapy
- Neoplasms